©2025 Stanford Medicine
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Not Recruiting
Trial ID: NCT05224661
Purpose
Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
Official Title
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Stanford Investigator(s)
Lori Muffly
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Inclusion Criteria:
1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Aged at least 18 years old at time of consent
4. Diagnosed with AML, in complete remission
1. Complete remission (CR) definition per local institutional criteria
2. CR with incomplete hematologic recovery (CRi) is not an exclusion criterion
3. MRD positivity is not an exclusion criterion
5. Undergoing alloHCT
6. Has a diagnostic AML specimen available
Exclusion Criteria:
1. Diagnosis of acute promyelocytic leukemia
2. Prior alloHCT
Intervention(s):
other: Prospective determination of the clinical utility of measurable residual disease (MRD) testing
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Audrey Xu
650-725-1647